NCT01393366已完成不适用
Facing Obstacles to RDI(Relative Dose Intensity)Through Telephone Intervention Strategy
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 6
- 主要终点
- Evaluation of RDI
研究概览
简要总结
The investigators plan to conduct a nurse-based telephone intervention study to minimize toxicity and increase compliance to a combination of Fludarabine-Cyclophosphamide-Rituximab (FCR) given frontline to Chronic Lymphocytic Leukemia patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •CLL whatever Binet stage, but with at least one NCIWG2008 criteria indicating a need for first line treatment.
- •Matutes score must be 4-5/
- •Initial cytopenia (due to CLL) are not exclusion criteria.
- •Lymph node biopsy is needed only if suspicion of Richter syndrome.
- •Mandatory pre-therapeutic check-up: FISH in search for deletion del17p and del11q, DAT test, haptoglobin levels, creatinine clearance.
- •Eligibility to a treatment with FCR: clearance > 60ml/mn, consider dose adjustments (recommended by protocol) if clearance30-60ml/mn, and comorbidity score CIRS-G≤
- •Signed informed consent
- •Age> or equal 18 years, ECOG PS 0-
- •Estimated overall survival>6 months.
- •Conserved liver function (bilirubin<2,5mg/dl, SGPT<4ULN, SGOT<4ULN) except infiltration due to the disease.
- •Contraception for younger patients.
- •Confident with the use of telephone, no disabling deafness.
排除标准
- •Richter syndrome or atypical CLL (Matutes score <4), and/or del17p by FISH
- •Relapse of CLL
- •Contra-indications to fludarabine: auto-immune cytopenia, creatinine clearance<30 ml/mn.
- •Serologies positive for HIV, HBV, or HCV. No active bacterial, viral or fungal infection
- •Previous history of hypersensibility to any product used in this protocol
- •Denial, or medical or psychological condition preventing completion of the signed informed consent.
- •Treatment with an investigational agent, or participation to another therapeutic protocol, 30 days before participating to this study.
- •Pregnant/breastfeeding women.
- •CNS involvement by CLL.
- •Presence of another cancer needing treatment (except basocellular carcinoma or cervix cancer managed with only surgery or local therapy).
结局指标
主要结局
Evaluation of RDI
时间窗: 3 years
Reductions in Relative Dose Intensity, calculated as the difference between initially planned doses of F, C and R and effectively prescribed doses of the 3 drugs, before and after 6 courses of FCR.
次要结局
- Evaluation of Toxicity grade III-IV(3 years)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
不适用
Nurse-Driven Telephone Intervention in Improving Side Effects in Cancer Patients Undergoing ChemotherapyBreast CarcinomaHead and Neck CarcinomaSarcomaNCT03964896M.D. Anderson Cancer Center90
已完成
不适用
Feasibility of Remote Tai ChiPTSDPain, ChronicNCT05693805Boston University42
已完成
不适用
Improving Health Behaviors Through Telephone Linked CareDietPhysical ActivitySmokingAlcohol AbuseNCT00314197American Academy of Family Physicians400
已完成
不适用
Reducing Readmission for Frail Elderly Patients With Decompensated Heart FailureFragilityEmergenciesHeart FailureAcute Decompensated Heart FailureNCT03246035Jewish General Hospital60
已完成
3 期
Dose De-escalation to the Elective Nodal Sites in Head and Neck CancerHead and Neck CancerNCT01812486Universitaire Ziekenhuizen KU Leuven200